Amarin (AMRN) Higher as Teva (TEVA) Said to be Waiting in the Wings for a Takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Groundhog Day for Amarin (AMRN); MKM Not Positive on NCE Status Although Company Remains Upbeat
November 19, 2012 10:42 AM ESTAnalysts at MKM Partners commented on Amarin Corporation (NASDAQ: AMRN) after the FDA updated the Orange Book for October and once again failed to rule on NCE status for Vascepa.
MKM's Jon LeCroy notes this is the fourth delay and he assumes that it is unlikely that Amarin will be able to successfully petition the FDA to grant Vascepa NCE status. However,... More
